Gilenya Off And Running, But Keeping Pace Long-Range Is Key
Executive Summary
Novartis AG's Gilenya (fingolimod) – the first oral treatment for multiple sclerosis – is off to a modestly strong start. The drug’s sales performance since its U.S. launch in October has been respectable, if not remarkable, driven by both market expansion and patient switches.
You may also be interested in...
Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
Relapse reduction in multiple sclerosis was robust, though lower than in the first Phase III trial, but the drug missed the statistical mark on disability progression.
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands